Ushkalova E A, Zyryanov S K, Shvarts G Ya
Russian University of People's Friendship, Moscow, Russia, 117198.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 11999; 'Teva' Ltd., Moscow, Russia, 115054.
Vestn Otorinolaringol. 2016;81(5):59-66. doi: 10.17116/otorino201681559-66.
The authors discuss the mechanism of action, effectiveness, and safety of intranasal glucocorticosteroids (inGCS) used to treat acute, recurrent and chronic rhinosinusitis (RS). The last version of the European guidelines concerning the application of inGCS assigns the highest level of evidence-Ia and the highest strength of recommendations-A to these medications when applied for the treatment of acute and polypoid rhinosinusitis. Moreover, they acquire the status of the agents of choice for the therapy of chronic RS without polyps. Mometasone furoate is one of the best explored preparations of this group of medicines. It is possessed of favourable pharmacodynamic and pharmacokinetic properties when prescribed for local application. The new mometasone furoate preparation in the form of an intranasal spray Dezrinit produced by "Teva" Ltd. was registered in the Russian Federation. In a comparative randomized clinical trial (RCT), the preparation was shown to be an equivalent to the Nasonex spray.
作者讨论了用于治疗急性、复发性和慢性鼻-鼻窦炎（RS）的鼻内糖皮质激素（inGCS）的作用机制、有效性和安全性。欧洲关于inGCS应用的最新指南版本将这些药物用于治疗急性和息肉样鼻-鼻窦炎时的证据水平定为最高的Ia级，推荐强度定为最高的A级。此外，它们成为治疗无息肉慢性RS的首选药物。糠酸莫米松是该类药物中研究得最充分的制剂之一。局部应用时，它具有良好的药效学和药代动力学特性。由“梯瓦”公司生产的新型糠酸莫米松鼻喷雾剂Dezrinit已在俄罗斯联邦注册。在一项比较随机临床试验（RCT）中，该制剂被证明与内舒拿喷雾剂等效。
